{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:43:28Z","timestamp":1783381408701,"version":"3.54.6"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, and somatic) syndrome is a newly described hemato-inflammatory acquired monogenic entity that presents in adulthood. One of the main features of VEXAS syndrome is a high venous thromboembolism (VTE) burden, with approximately 30\u201340% experiencing lower extremity deep vein thrombosis and a lower incidence of pulmonary embolism at approximately 10%. To date, VEXAS syndrome has not been associated with rarer forms of VTE such as cerebral sinus vein thrombosis (CSVT) and Budd\u2013Chiari syndrome, which are well-recognized vascular manifestations in Behcet\u2019s disease, another autoinflammatory vasculitic disease. Herein, we describe a case of acute severe extensive and fatal CSVT in a patient with VEXAS syndrome. The event occurred during a period of apparently quiescent inflammatory status, while the patient was receiving tocilizumab and a low dose of glucocorticoids. Despite treatment with anticoagulation, high-dose glucocorticoids, endovascular thrombectomy, and intracranial pressure-lowering agents, the patient suffered severe neurologic damage and ultimately succumbed to the condition 3\u2009weeks after the onset of CSVT. To the best of our knowledge, this is the first reported case of CVST in a patient with VEXAS syndrome.<\/jats:p>","DOI":"10.3389\/fmed.2024.1377768","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T04:52:09Z","timestamp":1712551929000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Case report: Cerebral sinus vein thrombosis in VEXAS syndrome"],"prefix":"10.3389","volume":"11","author":[{"given":"Michael","family":"Zisapel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Seyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Molad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hen","family":"Hallevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Mauda-Havakuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Jonas-Kimchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Elkayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Eviatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/nejmoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1053\/j.seminhematol.2021.10.006","article-title":"Thrombotic manifestations of VEXAS syndrome","volume":"58","author":"Groarke","year":"2021","journal-title":"Semin Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMra042354","article-title":"Thrombosis of the cerebral veins and sinuses","volume":"352","author":"Stam","year":"2005","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/art.24393","article-title":"Cerebral venous thrombosis in Beh\u00e7et\u2019s disease","volume":"61","author":"Saadoun","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.berh.2016.08.002","article-title":"Beh\u00e7et\u2019s disease: how to diagnose and treat vascular involvement","volume":"30","author":"Seyahi","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41584-022-00880-7","article-title":"Vascular Beh\u00e7et syndrome: from pathogenesis to treatment","volume":"19","author":"Bettiol","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1055753","DOI":"10.3389\/fmed.2023.1055753","article-title":"Innate immune responses in Beh\u00e7et disease and relapsing polychondritis","volume":"10","author":"Shimizu","year":"2023","journal-title":"Front Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00277-019-03625-x","article-title":"Thromboembolic events in polycythemia vera","volume":"98","author":"Griesshammer","year":"2019","journal-title":"Ann Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1182\/blood.V118.21.5245.5245","article-title":"Risk of venous thromboembolism in patients with Myelodysplatic syndrome","volume":"118","author":"Younes","year":"2011","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s1052-3057(98)80010-4","article-title":"Myelodysplastic syndrome and sagittal sinus thrombosis","volume":"7","author":"Finelli","year":"1998","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1159\/000446062","article-title":"Autoimmunity and inflammation in myelodysplastic syndromes","volume":"136","author":"Wolach","year":"2016","journal-title":"Acta Haematol"},{"key":"ref13","first-page":"S145","article-title":"A reappraisal of the association between Beh\u00e7et\u2019s disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review","volume":"33","author":"Esatoglu","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1161\/01.STR.0000173152.84438.1c","article-title":"Causes and predictors of death in cerebral venous thrombosis","volume":"36","author":"Canh\u00e3o","year":"2005","journal-title":"Stroke"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/BLOOD.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada","year":"2022","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/BLOOD.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","article-title":"The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis","volume":"27","author":"Samuelson","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ajh.27156","article-title":"VEXAS syndrome: clinical, hematologic features and a practical approach to diagnosis and management","volume":"99","author":"Koster","year":"2024","journal-title":"Am J Hematol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1377768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T04:52:11Z","timestamp":1712551931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1377768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":22,"alternative-id":["10.3389\/fmed.2024.1377768"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1377768","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"article-number":"1377768"}}